Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, May 2000, p. 412-416, Vol. 7, No. 3
Department of Internal Medicine, Division of
Infectious Disease, University of Texas Medical Branch, Galveston,
Texas
Received 5 October 1999/Returned for modification 9 December
1999/Accepted 26 January 2000
The relationship of the neutralizing activity (NA) profile of sera
from human immunodeficiency virus (HIV)-infected individuals to the HIV
viral load and the absolute CD4 count was examined. The NA of 24 serum
samples against autologous isolates (AI) and HIV type 1 strain MN was
examined. Three NA patterns were recognized. Nine sera neutralized both
AI and MN (+/+), six sera neutralized MN but not AI (
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Neutralization Profiles of Sera from Human
Immunodeficiency Virus (HIV)-Infected Individuals: Relationship to HIV
Viral Load and CD4 Cell Count
/+), and nine
sera failed to neutralize both AI and MN (
/
). The identification of
the three neutralization patterns (+/+,
/+, and
/
) indicated that
resistance to neutralization was progressive. A reciprocal relationship
between the viral burden of the patients and the NA profiles was
observed. The nine subjects with a
/
NA profile had a plasma viral
load of
5 × 104 copies/ml and a cellular viral
burden of
1,122 infectious units per million viable cells, which were
significantly different from those of the other groups
(P < 0.02). These patterns were independent of the
phenotypic characteristics of the virus. Longitudinally, subjects with
a
/
profile at baseline gained their HIV-specific NA by 24 weeks of
antiretroviral therapy when this was associated with a
1-log10 decline in the plasma HIV viral load. The sera from week 24 from some patients were able to neutralize both the 24-week and the baseline dominant virus isolates. A change in CD4 cell
count of 50 or more in either direction predicted a
/
or +/+
profile. The verification of the autologous NA profile might be
important in selecting patients who may benefit from immune-based
therapies involving neutralizing monoclonal antibodies.
*
Corresponding author. Mailing address: University of
Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0835. Phone: (409) 747-1856. Fax: (409) 747-1857. E-mail:
mnokta{at}utmb.edu.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»